The Value of Contraception to Prevent Perinatal HIV Transmission
July 18, 2006
The authors conducted the current study to highlight the value of preventing unintended pregnancies among HIV-infected women as a strategy to prevent perinatal HIV transmission. Their goal was to assess the cost-effectiveness of family planning programs to avert HIV-positive births with the current programmatic emphasis on prenatal care to provide and promote nevirapine for prevention of mother-to-child transmission.
The researchers conducted cost-effectiveness analyses from the health system perspective during one year with a hypothetical sub-Saharan African population. They combined expected program costs with the number of HIV-positive births averted for each strategy.
The investigators found that at the same level of expense, the contraceptive strategy averts 28.6 percent more HIV-positive births than nevirapine for prevention of mother-to-child transmission.
"Increasing contraceptive use among nonusers of contraception who do not want to get pregnant is cost-effective and is an equally important strategy to prevent perinatal transmission as prenatal care programs that provide and promote nevirapine to HIV-infected mothers," the researchers concluded.
Sexually Transmitted Diseases
06.06; Vol. 33; No. 6: P. 350-356; Heidi W. Reynolds, Ph.D., M.P.H.; Barbara Janowitz; Ph.D.; Rick Homan, Ph.D.; Laura Johnson, M.A.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.